

ORTH 345



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUL 13 1981

GROUP 120

Applicants : Patrick Chung-Shu Kung and  
Gideon Goldstein  
Serial No. : 33,669  
Filed : April 26, 1979  
For : HYBRID CELL LINE FOR PRODUCING COMPLEMENT-  
FIXING MONOCLONAL ANTIBODY TO HUMAN T  
CELLS, ANTIBODY AND METHODS  
Examiner : A. Fagelson  
Group : 125

Commissioner of Patents and Trademarks  
Washington, D. C. 20231

TERMINAL DISCLAIMER UNDER 37 CFR 1.321

Dear Sir:

Ortho Pharmaceutical Corporation, Raritan, New Jersey, a corporation of New Jersey, represents that it is the Assignee of the entire right, title, and interest in the above-identified patent application by virtue of an unrecorded assignment executed by Patrick C. Kung and Gideon Goldstein. On April 25, 1979, a copy of which is attached hereto.

Ortho Pharmaceutical Corporation hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration of any United States Patent granted on copending application Serial No. 22,132, filed March 20, 1979, and hereby agrees that any patent so granted on the subject application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to any patent issuing from application Serial No. 22,132, this agreement to run with any patent granted on the subject application and to be binding upon the grantee, its

51962 10/21/81 033669

10-0750 4 125

15.00CH

92

successors, or assigns.

Signed at Raritan, New Jersey this 1<sup>st</sup> day of  
July, 1981.

ORTHO PHARMACEUTICAL CORPORATION

BY:

Glenn F. Kiplinger

Glenn F. Kiplinger,  
Vice President  
Research and Development